The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrenkel Topping Regulatory News (FEN)

Share Price Information for Frenkel Topping (FEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 53.50
Bid: 53.00
Ask: 54.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.887%)
Open: 53.50
High: 53.50
Low: 53.50
Prev. Close: 53.50
FEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

7 Feb 2023 07:00

RNS Number : 0687P
Frenkel Topping Group PLC
07 February 2023
 

The information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended. With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

Frenkel Topping Group plc

("Frenkel Topping", the "Company" or the "Group") 

Trading Update for the year ended 31 December 2022

&

Notice of Results

Strong financial performance and delivery against strategy in FY2022

Positive start to FY2023, trading in line with expectations

Frenkel Topping (AIM: FEN), a specialist financial and professional services firm operating within the personal injury and clinical negligence marketplace, is pleased to provide the following trading update for the financial year ended 31 December 2022 ("FY2022") and an outlook for the current financial year ("FY2023").

The Board expects to report revenues in line with expectations of c.£24.8m (2021: £18.4m) and adjusted EBITDA of c.£6.1m* (2021: £4.6m) for FY2022. Pleasingly, EBITDA margin has been stable year on year at c25%. The Company had £5.0m of net cash at the year end and remains debt free. Assets Under Management ("AUM") has grown to £1,187m (2021: £1,174m) during the year £129m of new AUM was added within the advisory business.

This performance demonstrates the Company's resilience in a challenging financial market, as well as the progress made by the Company in diversifying revenue streams via its focused acquisition strategy and consolidation of the Personal Injury (PI) and Clinical Negligence (CN) space.

Of note is the performance of the Group's discretionary fund manager, Ascencia Investment Management ("Ascencia"), where assets on a DFM Mandate increased to £715m (2021: £676m).

Comparing Ascencia's positive performance against a backdrop of wider market contraction and material outflows further demonstrates Ascencia's success in managing multi-asset investment solutions that are positioned to capture the upside of market fluctuations, while aiming to reduce the negative impact of market turbulence on client assets.

Ascencia's strong performance in the previous financial year continued last year, with the core risk-rated strategies outperforming their respective Private Client Indices/ARC indices. It is testament to the Group's in-house strategy and approach to risk management and something the Board is justifiably proud of. The Company views the Ascencia platform as a clear growth opportunity in the coming years and a key tool to winning future business. Ascencia portfolios are currently defensively positioned given the uncertain and opaque investment outlook, with cash ready to be deployed should the opportunity arise.

The Company has of course not been entirely immune to challenging market conditions during the year. However, the modest impact on the Group's recurring revenue, has been replaced by transactional revenue delivered by the Group's businesses acquired during the last 3 years, proving out the strategy of diversifying revenue streams. By their nature the margin profile is a little different on the transaction revenue and certain essential staff costs and wage inflation has had a modest impact in the latter part of the year, as well as funding the start-up of Keystone Case Management.

The Company is also pleased to again report its outstanding client retention rates at 99%.

The Company continued to make significant progress delivering against its strategy of consolidating the pre-settlement professional services marketplace in the PI and CN space, positioning Frenkel Topping as a market leader in its sector. During the first part of the year the Company acquired Cardinal Management Limited, which is performing to plan, and it raised a further £10m in July 2022 to support the M&A strategy, completing two further acquisitions of Somek and Associates Ltd and N-Able Services Ltd in September 2022, both of which have performed to plan and in line with management's expectations.

Outlook

The new financial year has started well and the Board is confident that the acquisitions made to date will continue to contribute revenue and profitable growth to the Group. In January 2023, subsidiaries Forths Forensics and Bidwell Henderson Cost Consultants (BH) both delivered record revenues and BH surpassed its previous highest recorded number of files received by 20%. During the year the Board also expects Keystone Case Management to start contributing. Expectations for the year to FY2023 therefore remain unchanged as a result to of the solid start to the financial year.

Where appropriate the Company will endeavour to migrate AUM onto the Ascencia platform to be managed internally in order to mitigate, as far as possible, the impact of any future abnormal market movements which Ascencia has demonstrably been able to do during the year. It will also look to drive further synergies from the acquisitions made and integrate them further into a unified platform and offering by the Group. Finally, the Company is planning some investment in data analytics in order to better capture and optimise business development opportunities across the platform.

Notice of results and update on strategy

A comprehensive update and review of the year will be provided with the Company's annual results, as well as the presentation of an ambitious growth plan.

Final results for the year ended 31 December 2022 are expected to be announced on 24th April 2023. 

* The financial expectations noted above are preliminary, and subject to year-end financial close and audit review processes. Adj. EBITDA defined as before share based compensation, M&A strategy and re-organisation costs.

Richard Fraser, Chief Executive Officer of Frenkel Topping Group plc, said:  

"We are pleased to report on another year of delivery despite challenging market conditions. A backdrop of market volatility served to highlight the strength of the DFM subsidiary in the Company's portfolio as well as our strategy of diversifying revenue streams. We have executed the buy and build strategy outlined ahead of our capital raise and we are in a strong position to accelerate growth through the group in the coming years and to capitalise on a significant opportunity in the personal injury and clinical negligence space. I am incredibly proud of the teams efforts and look forward to updating shareholders on progress at the time of our results in April"

 

For further information:     

Frenkel Topping Group plc

www.frenkeltoppinggroup.co.uk

Richard Fraser, Chief Executive Officer

Tel: 0161 886 8000

finnCap Ltd (Nominated Advisor & Broker)

Tel: 020 7220 0500

Carl Holmes/Abigail Kelly/Milesh Hindocha (Corporate Finance)

Tim Redfern / Charlotte Sutcliffe (ECM)

About Frenkel Topping Group

The Frenkel Topping Group of companies specialises in providing financial advice and asset protection services to clients at times of financial vulnerability, with particular expertise in the field of personal injury (PI) and clinical negligence (CN).

For more than 30 years the Group has worked with legal professionals and injured clients themselves to provide pre-settlement, at-settlement and post-settlement services to help achieve the best long-term outcomes for clients after injury. It boasts a client retention rate of 99%.

Frenkel Topping Group is focused on consolidating the fragmented PI and CN space in order to provide the most comprehensive suite of services to clients and deliver a best-in-class service offering from immediately after injury or illness and for the rest of their lives.

The group's services include the Major Trauma Signposting Partnership service inside NHS Major Trauma Centres, expert witness, costs, tax and forensic accountancy, independent financial advice, investment management, and care and case management.

The Group's discretionary fund manager, Ascencia, manages financial portfolios for clients in unique circumstances, often who have received a financial settlement after litigation. In recent years Ascencia has diversified its portfolios to include a Sharia-law-compliant portfolio and a number of ESG portfolios in response to increased interest in socially responsible investing (SRI).

Frenkel Topping has earned a reputation for commercial astuteness underpinned by a strong moral obligation to its clients, employees and wider society, with a continued focus on its Environmental, Social and Governance (ESG) impact.

For more information visit: www.frenkeltoppinggroup.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEQLFBXLLZBBF
Date   Source Headline
23rd Apr 20247:00 amRNSInvestor Presentation via Investor Meet Company
22nd Apr 20247:01 amRNSAcquisition
22nd Apr 20247:00 amRNSFinal Results
12th Mar 20247:00 amRNSNotice of Results
20th Feb 20247:00 amRNSDirectorate Change
24th Jan 20247:00 amRNSTrading Update & New Debt Facility
22nd Dec 20238:00 amRNSHolding(s) in Company
13th Nov 20237:00 amRNSPartnership Programme Grows with New Joint Venture
8th Nov 20234:30 pmRNSDirector/PDMR Shareholding
3rd Nov 20238:30 amRNSHolding(s) in Company
3rd Oct 20237:00 amRNSThe Shares and AJ Bell Media investor event
3rd Oct 20237:00 amRNSAppointment of Strategy & Implementation Director
29th Sep 20237:00 amRNSInterim Results
31st Aug 202310:08 amRNSDirector/PDMR Shareholding
29th Aug 20237:00 amRNSDirector Share Purchase
22nd Aug 20237:00 amRNSTrading Update
31st Jul 20237:00 amRNSFEN Announces Joint Venture with Lime Solicitors
21st Jul 20233:20 pmRNSIssue of consideration shares
6th Jul 20237:00 amRNSFEN announces New Major Trauma Centre
20th Jun 20237:00 amRNSDirector/PDMR Shareholding
14th Jun 202312:20 pmRNSResult of AGM
5th Jun 20237:00 amRNSFEN announces New Major Trauma Centre
15th May 20234:15 pmRNSAnnual Report Posting, Notice of AGM & Dividend
24th Apr 20237:00 amRNSFinal Results
22nd Mar 20234:00 pmRNSHolding(s) in Company
15th Mar 202311:47 amRNSDirector/PDMR Shareholding
8th Mar 20237:00 amRNSInvestor Presentation
13th Feb 20237:00 amRNSFrenkel Topping Partnership Programme Grows
7th Feb 20237:00 amRNSTrading Update and Notice of Results
10th Nov 20222:50 pmRNSInterim Dividend Timetable
3rd Nov 20227:00 amRNSFEN to present at AJ Bell investor webinar
24th Oct 20222:30 pmRNSDirector/PDMR Shareholding and Holdings in Company
24th Oct 202212:15 pmRNSHolding(s) in Company
3rd Oct 20227:00 amRNSDirector/PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
13th Sep 20227:00 amRNSCompletion of Two Acquisitions
31st Aug 20222:15 pmRNSNotice of Results
3rd Aug 202210:17 amRNSHolding(s) in Company
3rd Aug 202210:15 amRNSHolding(s) in Company
29th Jul 202212:15 pmRNSResult of General Meeting
25th Jul 20227:00 amRNSFEN Announces Joint Venture with CFG Law
25th Jul 20227:00 amRNSFEN Announces Joint Venture with CFG Law
12th Jul 202210:50 amRNSHolding(s) in Company
6th Jul 20227:00 amRNSResults of Placing
5th Jul 20222:45 pmRNSProposed Placing to raise approximately £10m
22nd Jun 202211:40 amRNSResult of AGM
16th May 20228:25 amRNSAnnual Report Posting, Notice of AGM & Dividend
4th May 20221:00 pmRNSDirector/PDMR Shareholding
25th Apr 20227:00 amRNSFinal Results
15th Feb 20227:00 amRNSTrading Update and Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.